Stem cell differentiation within the human prostate epithelium: Implications for prostate carcinogenesis

BJU International, Supplement

Volumn 88, Issue 2, 2001, Pages 35-42

  Van Leenders, G J L H ^a   Schalken, J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Differentiation; Prostate; Review; Stem cell

Indexed keywords

ANDROGEN; CELL MARKER; GROWTH FACTOR RECEPTOR; KERATIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P63;

BASAL CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CONFERENCE PAPER; HOMEOSTASIS; HUMAN; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; STEM CELL; TUMOR GROWTH;

APOPTOSIS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; HOMEOSTASIS; HUMANS; KERATINS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, GROWTH FACTOR; STEM CELLS;

EID: 0034796118     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Epithelial stem cells in vivo
2. Stem cells: Attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt
3. Etiology and disease process of benign prostatic hyperplasia
4. Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate
5. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate
6. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumours and cultured cells
7. Keratin profiles in normal/hyperplastic prostates and prostate carcinoma
8. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate
9. Differential expression of specific cytokeratin polypeptides in the basal and luminal epithelia of the human prostate
10. Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma
11. Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma
12. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy
13. Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration
14. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer
15. Identification of intermediate cell types by keratin expression in the developing human prostate
16. Epithelial cell differentiation pathways in the human prostate: Identification of intermediate phenotypes by keratin expression
17. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: Simultaneous demonstration of cell-specific epithelial markers
18. Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bclx2: Cell kinetic features of neuroendocrine cells in the human prostate
19. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium
20. Proliferative heterogeneity in the human prostate: Evidence for epithelial stem cells
21. Immunohistochemical analysis of in vivo patterns of expression of CCP32 (Caspase-3), a cell death protease
22. Specific association of human telomerase activity with immortal cells and cancer
23. Telomerase activity: A prevalent marker of malignant human prostate tissue
24. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
25. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory prostate cancers
26. The Ki-67 protein: From the known and the unknown
27. The proliferative function of basal cells in the normal and hyperplastic human prostate
28. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells
29. Prostate stem cell compartments: Expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells
30. Cell proliferation studies in rat prostate. I. The proliferative role of basal and secretory epithelial cells during normal growth
31. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement
32. Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: Evidence for self-renewal of luminal cells
33. Ki-67 expression in early prostate cancer and associated pathological lesions
34. Histology and cellular kinetics of prostatic atrophy
35. Proliferative inflammatory atrophy of the prostate. Implications for prostatic carcinogenesis
36. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia
37. Cell-cell interaction in prostate gene regulation and cytodifferentiation
38. Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues
39. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma
40. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate
41. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate
42. Identification and preliminary characterization of two related proliferation-associated nuclear phosphoproteins
43. A novel M(r) 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal
44. Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer
45. Modulation of oncogenic potential by alternative gene use in human prostate cancer
46. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer
47. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities
48. p63 is a prostate basal cell marker and is required for prostate development
49. Neuroendocrine differentiation in prostatic carcinoma
50. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression
51. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP
52. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells
53. Anticytokeratin antibody 34âE12 staining in prostate carcinoma
54. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: A study of 100 cases of metastatic and locally advanced prostate cancer
55. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer
56. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment
57. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells
58. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase